Abbvie Inc Dossier
|
SectorHealth Care IndustryDrug Manufacturers - General Beta (adjusted)0.53 Intrinsic Value $195.20median of 5 methods · middle span $178-$260based on filings through 30 Jun 2026 Market Price $283.40Price as of 15 Oct 2026 OvervaluedIntrinsic value is 31% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $500.8B Enterprise Value $558.7B Shares Outstanding 1.8B diluted Moat Rating Wide Next Earnings Date30 Oct 2026 Last ex-dividend15 Jul 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary AbbVie's operating momentum is strong: second-quarter 2026 revenue increased 10.2%, while Skyrizi, Rinvoq and neuroscience revenue each grew more than 20%. Recent indication approvals and submissions support further portfolio expansion. The offset is continuing Humira erosion, weakness in oncology and aesthetics, and execution and capital-allocation risk from the proposed $10.9 billion Apogee acquisition. The neutral view is provisional and reflects balanced operating evidence rather than a valuation-based return forecast. This section is the 12-month view: analyst targets and the scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$200.00 Mean target$276.41 High · most bullish analyst$328.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $200.00 Skyrizi or Rinvoq growth decelerates materially, Humira erosion remains severe, and persistent oncology or aesthetics weakness reduces diversification. Apogee integration, development setbacks or higher-than-disclosed transaction economics further pressure earnings quality and investor confidence. Base CaseCentral scenario $276.41 Matches the consensus meanSkyrizi, Rinvoq and neuroscience remain the principal growth engines and more than offset most Humira erosion, but growth moderates from second-quarter 2026 levels. Apogee closes and initially dilutes 2026 adjusted EPS as disclosed, while oncology and aesthetics remain mixed. Bull CaseUpside scenario $328.00 Skyrizi and Rinvoq sustain growth near their second-quarter 2026 rates, neuroscience remains a double-digit growth contributor, and recent regulatory successes broaden eligible patient populations. Successful integration of Apogee adds credible late-stage immunology options without materially disrupting earnings momentum. Scenarios are anchored to street consensus at the research date, with our rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |